A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

Memory change is not always a part of normal aging, with more than 7 million adults living with Alzheimer’s disease in the ...

Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience, will ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on genetics and financial implications.

The spot, which prominently utilizes a cover of “Here Comes the Sun” by The Beatles, manages to balance a message of hope with the somber nature of Alzheimer’s.

Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli Lilly (NYSE:LLY) is looking at other targets as well. The drugmaker's ...

Eli Lilly's phase three trial on more than 1,700 patients found that donanemab slowed the progression of Alzheimer's by 29% compared to a placebo after around 18 months, based on a traditional ...

The U.S. Food and Drug Administration has postponed a decision on Eli Lilly’s potential Alzheimer’s treatment donanemab with an unusual request to have an advisory committee examine the drug.

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...